WLLW vs. VPH, CTX, DN, LABS, CWEB, MDP, ATE, and RVX
Should you be buying Willow Biosciences stock or one of its competitors? The main competitors of Willow Biosciences include Valeo Pharma (VPH), Crescita Therapeutics (CTX), Delta 9 Cannabis (DN), MediPharm Labs (LABS), Charlotte's Web (CWEB), Medexus Pharmaceuticals (MDP), Antibe Therapeutics (ATE), and Resverlogix (RVX). These companies are all part of the "medical" sector.
Willow Biosciences (TSE:WLLW) and Valeo Pharma (TSE:VPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.
Willow Biosciences has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Valeo Pharma has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500.
Willow Biosciences received 13 more outperform votes than Valeo Pharma when rated by MarketBeat users. However, 100.00% of users gave Valeo Pharma an outperform vote while only 82.35% of users gave Willow Biosciences an outperform vote.
Willow Biosciences has higher earnings, but lower revenue than Valeo Pharma. Willow Biosciences is trading at a lower price-to-earnings ratio than Valeo Pharma, indicating that it is currently the more affordable of the two stocks.
0.1% of Willow Biosciences shares are held by institutional investors. Comparatively, 7.2% of Valeo Pharma shares are held by institutional investors. 27.3% of Willow Biosciences shares are held by company insiders. Comparatively, 47.1% of Valeo Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Valeo Pharma had 1 more articles in the media than Willow Biosciences. MarketBeat recorded 1 mentions for Valeo Pharma and 0 mentions for Willow Biosciences. Valeo Pharma's average media sentiment score of 0.75 beat Willow Biosciences' score of 0.00 indicating that Valeo Pharma is being referred to more favorably in the news media.
Willow Biosciences has a net margin of 0.00% compared to Valeo Pharma's net margin of -52.37%. Valeo Pharma's return on equity of 0.00% beat Willow Biosciences' return on equity.
Summary
Valeo Pharma beats Willow Biosciences on 10 of the 15 factors compared between the two stocks.
Get Willow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WLLW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WLLW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Willow Biosciences Competitors List
Related Companies and Tools
